Skip to main content
Cardiff Oncology, Inc. logo

Cardiff Oncology, Inc. — Investor Relations & Filings

Ticker · CRDF ISIN · US14147L1089 LEI · 549300AHOLZBHHYFWP04 US Professional, scientific and technical activities
Open in API
Filings indexed 1,012 across all filing types
Latest filing 2025-05-14 Regulatory Filings
Country US United States of America
Listing US CRDF

About Cardiff Oncology, Inc.

https://cardiffoncology.com/

Cardiff Oncology, Inc. is a clinical-stage biotechnology company developing novel cancer therapies. The company's primary focus is on leveraging the inhibition of Polo-like kinase 1 (PLK1), a well-validated oncology drug target. Its lead drug candidate, onvansertib, is an oral PLK1 inhibitor being evaluated in clinical trials. These programs test onvansertib in combination with standard-of-care therapeutics for various cancer indications. The company's strategy is designed to target tumor vulnerabilities to overcome treatment resistance and improve clinical outcomes for patients with significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2025
Regulatory Filings
2025-05-14 English
Regulatory Filings 2025
Regulatory Filings Classification · 100% confidence The document is a letter from Cardiff Oncology, Inc. to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-3. It references a filing (Form S-3) and requests the SEC to declare it effective at a specific time. The content is a formal correspondence related to a securities registration process, not a financial report, earnings release, or other detailed filings. The document length is short (1187 characters), and it is a regulatory communication rather than a report or announcement of financial results. This fits the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2025-05-12 English
S-3/A
Capital/Financing Update Classification · 95% confidence The document is a Form S-3/A registration statement amendment filed with the U.S. Securities and Exchange Commission. It is a registration statement under the Securities Act of 1933, used for registering securities offerings. The text includes a prospectus describing the offering of common stock, preferred stock, debt securities, warrants, and units, with a total offering amount up to $400 million. It is not a financial report, earnings release, or management discussion, but rather a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief notice, so it is not a Report Publication Announcement or Regulatory Filing. Hence, the classification is CAP with high confidence.
2025-05-08 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 8, 2025, reporting the results of operations and financial condition for the first quarter ended March 31, 2025. It mentions a press release announcing company highlights and financial results for the quarter, furnished as an exhibit. The document itself is short (2824 characters) and primarily serves as a current report filing to announce the earnings release. According to the classification rules, initial announcements of quarterly financial results (key highlights only) correspond to an Earnings Release (ER). Therefore, this document is best classified as an Earnings Release (ER).
2025-05-08 English
10-Q
Interim / Quarterly Report Q1 2025
2025-05-08 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A proxy statement filed with the SEC, specifically titled as "Definitive Additional Materials" related to the Annual Meeting of Stockholders of Cardiff Oncology, Inc. It includes notice of the availability of proxy materials and the 2024 Annual Report on Form 10-K, but does not contain the full proxy statement or the annual report itself. The document primarily serves to inform shareholders about the meeting, proposals to be voted on, and how to access the full proxy materials and annual report online. It is not the proxy statement itself nor the annual report, but rather a notice and summary directing shareholders to the full materials. According to the classification rules, such a document is best classified as a Proxy Solicitation & Information Statement (PSI) because it is part of the proxy materials and solicits shareholder votes, but is not the full report or the voting results. The document length (4989 characters) and content confirm it is not a full report but a solicitation notice and summary.
2025-04-30 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.